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Background. Studies about transmission rates of extended-spectrum β-lactamase (ESBL)–producing Entero-
bacteriaceae in hospitals and households are scarce.
Methods. Eighty-two index patients with new carriage of ESBL-producing Escherichia coli (ESBL-Ec; n = 72)
or ESBL-producing Klebsiella pneumoniae (ESBL-Kp; n = 10) and their hospital (n = 112) and household (n = 96)
contacts were studied prospectively from May 2008 through September 2010. Isolates were phenotypically and
molecularly characterized (sequencing of bla genes, repetitive extragenic palindromic polymerase chain reaction,
pulse-ﬁeld gel electrophoresis, and multilocus sequence typing). Transmission was deﬁned as carriage of a clonally-
related ESBL producer with identical blaESBL gene(s) in the index patient and his or her contact(s).
Results. CTX-M-15 was the most prevalent ESBL in ESBL-Ec (58%) and ESBL-Kp (70%) in the index patients.
Twenty (28%) ESBL-Ec isolates were of the hyperepidemic clone ST131. In the hospital, transmission rates were 4.5%
(ESBL-Ec) and 8.3% (ESBL-Kp) and the incidences of transmissions were 5.6 (Ec) and 13.9 (Kp) per 1000 exposure days,
respectively. Incidence of ESBL-Kp hospital transmission was signiﬁcantly higher than that of ESBL-Ec (P < .0001),
despite implementation of infection control measures in 75% of ESBL-Kp index patients but only 22% of ESBL-Ec index
patients. Detection of ESBL producers not linked to an index patient was as frequent (ESBL-Ec, 5.7%; ESBL-Kp, 16.7%)
as nosocomial transmission events. In households, transmission rates were 23% for ESBL-Ec and 25% for ESBL-Kp.
Conclusions. Household outweighs nosocomial transmission of ESBL producers. The effect of hospital infection
control measures may differ between different species and clones of ESBL producers.
Since the late 1980s, extended-spectrum β-lactamase
(ESBL)–producing Enterobacteriaceae, mainly Klebsiella
pneumoniae, have been recognized as a major cause of
nosocomial infections and outbreaks [1]. However,
during the late 1990s, blaESBL genes have increasingly
been identiﬁed within the community setting in the
context of urinary tract infections (UTIs) caused by Es-
cherichia coli [2, 3]. Currently, the CTX-M-15 is recog-
nized as the most widely distributed blaESBL among
Enterobacteriaceae [4, 5], and the worldwide spread of
the E. coli hyper-epidemic clone of sequence type (ST)
131 represents one of the major challenges for the
healthcare systems [6, 7].
An important strategy for controlling the spread of
these multidrug-resistant pathogens is the identiﬁcation
of patients with risks for acquisition [2, 8]. In addition,
active surveillance and isolation precautions are recom-
mended (http://www.premierinc.com/safety/topics/guide
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lines/cdc_guidelines.jsp). However, proposed guidelines refer to
the outbreak situations only and data about the efﬁciency of in-
fection control measures in the endemic hospital setting or even
in the community are currently not available [9, 10].
Community spread of ESBL producers indicates that
person-to-person transmission may occur outside the hospital
but data regarding household spread and risk factors thereof
are still limited [11, 12]. Prolonged carriage of ESBL producers
in the gastrointestinal tract of patients after hospital discharge
may enhance such transmission [13]. Thus, a better under-
standing of the transmission dynamics of ESBL producers in
this setting is warranted in order to guide measures for the
control of ESBL producers in the community.
In the present study, we prospectively evaluated transmis-
sion rates of ESBL-producing E. coli (ESBL-Ec) and ESBL-
producing K. pneumoniae (ESBL-Kp) from hospital index
patients to hospital roommates and to household persons.
Our data indicate that the transmission rate is signiﬁcantly
higher within households than in our non-outbreak hospital
scenario.
METHODS
Study Setting and Recruitment of Patients
A prospective, longitudinal study was conducted from 1 May
2008 through 30 September 2010. Index patients and their
hospital contacts were recruited from 1 May 2008 through 30
September 2009 at the University Hospital of Bern (Bern,
Switzerland), a 1033-bed tertiary-care hospital with a 30-bed
mixed intensive care unit (ICU), and more than 35 000 admis-
sions resulting in 280 000 patient-days per year. Index patients
included pediatric (age, <10 years) and adult patients hospital-
ized or treated as outpatients at the study center presenting
with a newly detected carriage or infection with ESBL-Ec or
ESBL-Kp. The study was conducted in accordance with local
requirements of the ethics committee.
Deﬁnitions
Patients were categorized as inpatients if they required admis-
sion to the hospital for >24 hours. An index patient was
deﬁned as an inpatient or outpatient with a newly recognized
infection or colonization with ESBL-Ec or ESBL-Kp isolates.
Hospital contact patients were deﬁned as roommates who
shared the same wardroom, ICU room, or immediate care
room for ≥48 hours with an index patient. Household contact
persons were deﬁned as persons who shared the same house-
hold with the index patient on a regular basis. Transmission
was assumed when the index patient and contacts shared a
clonally-related (see below) ESBL-Ec or ESBL-Kp isolate with
identical blaESBL gene(s).
Data Collection
For inpatients and outpatients included in the study, the pres-
ence of the following risk factors for ESBL carriage active
during the previous 3 months were considered: previous hos-
pitalization, ICU stay, surgical procedures, use of indwelling
devices (ie, intravascular and urinary catheters, endotracheal
and naso-gastric tubes, tracheostomy, and drainages), perito-
neal- or hemodialysis, urinary or fecal incontinence, recurrent
UTI, intermittent self-catheterization or other chronic urologic
conditions, presence of skin lesions, domestic or livestock
animal husbandry, antibiotic treatment, immunosuppressive
therapy (ie, ≥20 mg/d of prednisone, radiotherapy, chemo-
therapy, or immunomodulators). The presence and severity of
comorbidity was assessed at recruitment by calculating the
Charlson comorbidity index [14]. The patient setting (eg,
long-term care facility, acute care hospital, or private house-
hold) was recorded at recruitment (see below).
Infection Control Policy
According to local infection control guidelines, patients with
ESBL carriage were put in contact isolation if they presented
with any of the above-mentioned risk factors. The isolation
protocol involved use of gloves by medical personnel during
any physical contact and medical procedure. Occupation of a
2-bed room was possible if the neighboring patient did not
present any of these risk factors (which are assumed to
enhance the risk of transmission). For ICU patients, isolation
measures were implemented in 4-bed rooms. Hospital-wide
hand hygiene compliance is monitored on a yearly basis since
2005 using the SwissNOSO methodology. Overall, compliance
was 62% in 2008, 63% in 2009, and 68% in 2010 (http://www.
swissnoso.ch).
Screening and Follow-up Program
The follow-up period for inpatients and outpatients and their
contacts was 12 months except for death or stay abroad. For
index inpatients, screening samples were obtained at time of
ﬁrst detection of the ESBL-producing organism and weekly
thereafter until hospital discharge. After discharge of the
index patient, samples were also collected from the household
contact persons at 3-month intervals. Screening samples in-
cluded a fecal sample and, for index patients only, urine
samples in the case of a Foley catheter, respiratory samples in
case of intubation or tracheostomy and, if applicable, drainage
ﬂuid samples and swabs from skin lesions. Screening was
stopped if the index patient and his or her household contacts
tested negative in 2 consecutive screenings. For index outpa-
tients, a fecal sample was obtained at time of ﬁrst detection of
the ESBL producer and trimonthly thereafter. In addition,
screening samples were obtained in case of hospitalization at
the study center during the follow-up period. Hospital contact
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patients were screened weekly until 1 week after physical sepa-
ration from the index patient and at hospital discharge if the
last screening was performed >7 days before discharge.
Detection and Phenotypic Analysis of Isolates
Stool samples were analyzed with different selective culture
media designed to detect cephalosporin-resistant isolates:
ChromID ESBL agar, BLSE agar, a bi-plate with 2 selective
media (MacConkey agar plus ceftazidime and Drigalski agar
plus cefotaxime at a concentration of 2 and 1.5 mg/L, respec-
tively), and CHROMagar ESBL. Growing colonies were
subject to species identiﬁcation by use of standard biochemical
methods and the Vitek 2 system. Phenotypic conﬁrmation of
ESBL production was obtained by using the double-disk
synergy test with ceftazidime, cefpodoxime, and aztreonam in
combination with amoxicillin-clavulanate [15]. Coresistance to
other antibiotics was assessed by disk diffusion and interpret-
ed according to the Clinical Laboratory Standards Institute
criteria [16]. Multidrug-resistant isolates were resistant to at
least 1 representative of ≥3 antimicrobial classes as described
elsewhere [6].
Molecular Characterization of ESBL-Producing Isolates
Polymerase chain reaction (PCR) for blaTEM and blaSHV genes
was performed as reported elsewhere [17, 18]. For blaCTX-M
genes, universal primers were used as an initial screen reveal-
ing the distinct CTX-M groups 1, 2, and 4 [19]. Subsequently,
blaCTX-M group speciﬁc primers were used for ampliﬁcation
and sequencing CTX-Ms of group 1 (CTX-M_F_Grp1, TGG
TTAAAAAATCACTGCGYCA; CTX-M_R_Grp1, GTYGGT
GACGATTTTAGCC; CTX-M_R2_Grp1, ACAGAYTCGGTT
CGCTTTCA), group 2 (CTX-M_F_Grp2, AATGTTAACGGT
GATGGCGA; CTX-M_R_Grp2, GATTTTCGCCGCCGCA),
and group 4 (CTX-M_F_Grp4, AGAGARTGCAACGGAT
GATGT; CTX-M_R_Grp4, CCCYTYGGCGATGATTCTC;
CTX-M_F2_Grp4, CAGACGTTGCGTCAGCTTAC).
DNA sequencing was done according to the manufacture’s
instructions using the ABI 3130 sequencer. Sequences were
analyzed using MEGA 4 [20], translated into protein sequenc-
es, and compared with those previously described (http://
www.lahey.org/Studies/). Two new TEM types were identiﬁed
(ie, TEM-191 and TEM-192; accession numbers JF949915 and
JF949916, respectively).
Analysis of Clonal Relatedness
Phylogenetic groups (ie, A, B1, B2, and D) of ESBL-Ec were
determined as reported elsewhere [21]. Multilocus sequence
typing for selected ESBL-Ec and ESBL-Kp isolates was per-
formed according to the Achtman and Pasteur schemes, re-
spectively [22, 23]. Furthermore, all ESBL-Ec of phylogenetic
group B2 were tested for the pabB allele to detect those of
ST131 according to the Achtman scheme [24].
The relatedness of ESBL-Ec and ESBL-Kp isolates was also
analyzed by pulse-ﬁeld gel electrophoresis (PFGE) using the
XbaI restriction enzyme and the repetitive extragenic palin-
dromic PCR (rep-PCR) [25, 26]. Resulting rep-PCR and PFGE
ﬁngerprints were analyzed using bioanalyzer and GEL-
COMPAR II software. The cosine coefﬁcient and unweighted
pair group method with arithmetic means was used for cluster
analysis. ESBL-Ec isolates were deﬁned as clonally-related when
they shared the same phylogenetic group, >85% genetic related-
ness by rep-PCR and similar PFGE band patterns as deﬁned by
the Tenover criteria (ie, differing by ≤3 bands) [26]. Clonally-
related ESBL-Kp isolates were deﬁned as those of ESBL-Ec but
the rep-PCR cutoff was >90%.
Statistical Analysis
Using STATA version 10, continuous and categorical variables
were tested by the Student t test and the Fisher exact test
(2-tailed), respectively. Kaplan–Meier curves were derived by
Prism software and differences calculated using the log-rank
test.
RESULTS AND DISCUSSION
Molecular Characteristics and Antibiotic Resistance Patterns of
ESBL-Producing Isolates of Index Patients
A total of 82 index patients (48 inpatients and 34 outpatients)
with an infection or colonization due to ESBL-Ec (n = 72) or
ESBL-Kp (n = 10) were included into the study (Table 1). New
index cases were detected with a median frequency of 4.8
(range, 1–9) patients per month but there was no outbreak sit-
uation (Figure 1). The mean incidence of index inpatients was
0.12 cases per 1000 patient-days (48 index inpatients for a
total of 400 000 patient-days) in accordance with a recent
German study in which an incidence of 0.12 cases per 1000
patient-days was observed [27].
Overall, the CTX-M-15 producers were the most prevalent
ESBL-Ec (n = 42) and ESBL-Kp (n = 7) isolates (Table 1).
ESBL-Ec clustered mainly within phylogenetic groups A, B2,
and D. Twenty (28%) isolates were of ST131 according to the
Achtman scheme (Table 1). Presence of blaCTX-M-15 was asso-
ciated with resistance to ciproﬂoxacin and gentamicin
(P < .001 and P < .001, respectively). As previously observed,
ciproﬂoxacin resistance was highly prevalent among ESBL-Ec
of ST131 [6].
Characteristics of Index Patients and Sampling of ESBL-
Producing Isolates
As shown in Table 2, 13% of index patients were children. An
earlier Swiss study had already indicated that this population
Spread of ESBLs Within Hospital and Households • CID 2012:55 (1 October) • 969
Table 1. Molecular Characteristics and Antibiotic Resistance Patterns of Extended-Spectrum β-Lactamase–Producing Escherichia
coli and Klebsiella pneumoniae Isolates
Species and Phylogenetic Group, No. (%)
Parameter Ec A Ec B1 Ec B2 (pabB−) Ec B2 (pabB+)a Ec D Ec (all) Kp (all) Total
Total 21 7 3 20 21 72 10 82
ESBL genes
blaCTX-M-1 4 (19) 1 (14) 0 (0) 0 (0) 1 (5) 6 (8) 0 (0) 6 (7)
blaCTX-M-14 1 (5) 0 (0) 0 (0) 3 (15) 3 (14) 7 (10) 1 (10) 8 (10)
blaCTX-M-15 12 (57) 2 (29) 1 (33) 14 (70) 13 (62) 42 (58) 6 (60) 48 (59)
blaCTX-M-15 and blaSHV-5 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (10) 1 (1)
blaCTX-M-27 0 (0) 1 (14) 0 (0) 1 (5) 1 (5) 3 (4) 0 (0) 3 (3)
blaSHV-2/-2A/-5/-12 1 (5) 0 (0) 1 (33) 1 (5) 0 (0) 3 (4) 2 (20) 5 (6)
Other 1 (5) 3 (43) 1 (33) 1 (5) 2 (10) 8 (11) 0 (0) 8 (10)
Unknown blaESBL 2 (10) 0 (0) 0 (0) 0 (0) 1 (5) 3 (4) 0 (0) 3 (4)
Resistance phenotypeb
Gentamicin 8 (38) 2 (29) 2 (67) 11 (55) 13 (62) 36 (50) 10 (100) 46 (56)c
Ciprofloxacin 15 (71) 4 (57) 0 (0) 17 (85) 12 (57) 48 (67) 8 (80) 56 (68)d
Trimethoprim-sulfamethoxazole 17 (81) 6 (86) 2 (67) 12 (60) 17 (81) 54(75) 9 (90) 63 (77)
Piperacillin-tazobactam 10 (48) 2 (29) 0 (0) 5 (25) 1 (5) 18 (25) 7 (70) 25 (30)
MDR isolatese 10 (48) 3 (43) 0 (0) 9 (45) 7 (33) 29 (40) 9 (90) 38 (46)
Abbreviations: Ec, Escherichia coli; ESBL, extended-spectrum β-lactamase; Kp, Klebsiella pneumoniae; MDR, multidrug-resistant.
a Phylogenetic group B2 with pabB gene are indicative for sequence type 131 according to the Achtman multilocus sequence typing scheme.
b Intermediate susceptibility was grouped as resistant.
c Thirty-six of 46 isolates carried blaCTX-M-15 (P < .001).
d Forty-one of 56 isolates carried blaCTX-M-15 (P < .001).
e MDR isolates were resistant to at least 1 representative of ≥3 antimicrobial classes as described elsewhere [6].
Figure 1. Number of new patients with extended-spectrum β-lactamase–producing Klebsiella pneumoniae or Escherichia coli isolates detected from
May 2008 through September 2009. Data on E. coli are stratiﬁed according to the phylogenetic groups A, B1, B2, and D. E. coli isolates of group B2
which are positive for the pabB gene are indicative for sequence type 131 according to the Achtman multilocus sequence typing scheme [24]. Abbrevi-
ations: Ec, Escherichia coli; Kp, Klebsiella pneumoniae.
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may be an important reservoir of ESBL producers [28]. In ac-
cordance with the literature, the urinary tract was the most
frequent source of ESBL producers [2]. Index inpatients had
more severe underlying disease and were more frequently re-
ferred from a hospital setting compared with the index outpa-
tients. Almost all index patients had received antibiotic
treatment during the 3 months prior to the detection of ESBL
producers (Table 2).
The mean (± SD) time between collection of the initial
sample and the ﬁrst screening was 18.4 days (± 29.7). Fecal
carriage of an identical ESBL producer as found in the clinical
sample was detected in the initial screening in 65% of outpa-
tients and 71% of inpatients, which is comparable with a pre-
vious study [11]. Index inpatients stayed in the hospital for a
mean (± SD) of 34.6 days (± 37.1). Carriage of an ESBL pro-
ducer was detected within 48 hours after hospital entry in 20
(42%) of the index inpatients (data not shown).
Transmission Dynamics in the Hospital
A total of 88 hospital patients were exposed for 715 days to
the 40 index in patients with ESBL-Ec for a mean (± SD) of
8.1 days (± 5.8). The mean (± SD) follow-up time of the hos-
pital contacts was 27.6 days (± 40.0). An ESBL-Ec was found
in 9 of 88 (10.2%) contact patients (Supplementary Figure 1).
According to the study deﬁnition, transmission from the
index patient was assumed for 4 contacts (ie, patients 36, 16,
110, and 70; Figure 2). The overall transmission rate for ESBL-
Ec was therefore 4.5% (4 of 88 exposed contacts), correspond-
ing to an incidence of transmission of 5.6 cases per 1000
exposure days. The observed transmission rates were consis-
tent with a report with a transmission rate of 2.8% and 4.2
cases per 1000 exposure days [29].
A total of 24 hospital patients were exposed to the 8 index
in patients with ESBL-Kp during 144 days for a mean (± SD)
of 6.0 days (± 4.3). ESBL-Kp was found in 7 of 24 (29.1%)
hospital contacts (Supplementary Figure 1) but transmission
was plausible for only 2 contacts (8.3%; incidence, 13.8 cases
per 1000 exposure days; Figure 2). Therefore, the transmission
rate was higher for ESBL-Kp (8.3%) than for ESBL-Ec (4.5%),
albeit the difference did not reach statistical signiﬁcance.
However, the incidences of ESBL-Ec (5.6 cases per 1000 expo-
sure days) and ESBL-Kp (13.8 cases per 1000 exposure days)
transmission resulted in a signiﬁcantly higher incidence of
ESBL-Kp transmission (P < .0001). This suggests that ESBL-Kp
has a higher transmission potential than ESBL-Ec, in
accordance with the frequency of ESBL-Kp nosocomial
outbreaks being reported in the literature (Supplementary
Data). Notably, the ESBL-Kp STs involved in transmission
events were ST11 and ST323, which have been identiﬁed as
frequently detected clones also carrying blaKPC [30].
Table 2. Characteristics of the 82 Index Patients Carrying
Extended-Spectrum β-Lactamase–Producing Isolates
Value for Index Patients
(n = 82)
Parameter Outpatients Inpatients
Total 34 48
Age in years, mean ± SD 39.8 ± 23.3 58.2 ± 21.5
<10 7 4
10–50 14 5
>50 13 39
Female, No. (%) 29 (85) 23 (48)
Charlson score, mean ± SD 1.0 ± 2.3 3.0 ± 2.7a
Charlson score, age adjusted,
mean ± SD
1.7 ± 2.6 4.7 ± 3.3a
Referred from, No. (%)
Household 34 (100) 25 (52)
Other hospital 0 (0) 11 (23)
Long-term care facility 0 (0) 4 (8)
Other 0 (0) 4 (8)
Unknown 0 (0) 4 (8)
Type of sample with ESBL
producer detected, No. (%)
Urine 32 (94) 27 (56)
Blood culture 0 (0) 5 (10)
Tracheal aspirates 0 (0) 3 (6)
Wound 0 (0) 4 (8)
Feces 0 (0) 2 (4)
Other 2 (6) 7 (15)
Antibiotic exposure during the
3 months before referring
to hospital, No. (%)
Yes 30 (88) 39 (81)
No 2 (6) 0 (0)
Unknown 2 (6) 9 (19)
Antibiotic treatment at
sampling date, No. (%)
Yes 14 (41) 32 (67)
No 15 (44) 5 (10)
Unknown 5 (15) 11 (23)
Bacterial species with ESBLs,
No. (%)
Escherichia coli 32 (94) 40 (83)
Klebsiella pneumoniae 2 (6) 8 (17)
Initial screening of stool
samples, No. (%)
ESBL producer of the
identical speciesb
22 (65) 34 (71)
ESBL producer of different
speciesb
0 (0) 5 (10)
No ESBL producers
detected
10 (29) 7 (15)
No initial screening done 2 (6) 2 (4)
Abbreviations: ESBL, extended-spectrum β-lactamase; SD, standard deviation.
a Data were not available for 3 index patients.
b When compared with the first ESBL-producing isolate.
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Effect of Isolation Precautions in the Hospital
Most of the index patients with ESBL-Ec (75%) were not
under isolation precautions during exposure of the contacts
(537 of 715 exposure days). In contrast, only 22% of ESBL-Kp
index patients (32 of 144 exposure days) were not in isolation
(P < .001). Therefore, one might have expected a higher trans-
mission rate for ESBL-Ec than ESBL-Kp, whereas the opposite
was observed, in agreement with a higher transmission poten-
tial of ESBL-Kp as discussed above. However, the interpreta-
tion of this result requires some caution. In this study, index
patients were only isolated if they had risk factors for trans-
mission. Therefore, index patients with ESBL-Kp were likely
more prone to serve as a source of transmission than index
patients with ESBL-Ec. Furthermore, ESBL-Kp-colonized
index patients were more often in the ICU for at least 1 day
(n = 4; 50%) than the ESBL-Ec-colonized index patients (n =
11; 27.5%) and might therefore have been undergoing more
clinical procedures leading to transmission.
Transmission Dynamics in the Household Setting
ESBL-Ec carriage was found in 31 (35.2%) of 88 household
contacts, but based on the molecular analysis, transmission
was plausible for only 20 (22.7%) contacts (20 transmissions
within 17 Ec-household clusters; Figure 3). A Spanish study
revealed a lower rate of transmission among household mem-
bers of 6 of 54 contacts (11.1%), but this may be explained by
the different methodology of the studies [11]. Interestingly, in
our study, there were 6 mother-to-child and 2 child-to-child
pairs, which again suggest an important role for children in the
ESBL epidemiology (Figure 3). With regard to the ESBL-Ec, the
phylogenetic groups B2 (8 of 28 contacts) and D (9 of 34 con-
tacts) tended to be more often transmitted within households
than groups A (3 of 19 contacts) and B1 (0 of 7 contacts),
although this difference did not reach statistical signiﬁcance
(P = .1). Nevertheless, the result is in accordance with groups
B2 and D being more transmittable and virulent [21, 31].
Comparable with ESBL-Ec, the household transmission rate
of ESBL-Kp was 25% (2 of 8 contacts). Because previous stu-
dies were limited to ESBL-Kp transmission in hospitals [32, 33],
we are unable to compare our results with other studies, but
we note that the ESBL-Kp STs involved in household trans-
mission were of ST15 and ST147, which have been described
elsewhere as epidemic [34].
Overall, for both ESBL-Ec and ESBL-Kp the net transmis-
sion rate was higher within the household than in the hospital,
although this difference reached statistical signiﬁcance only for
ESBL-Ec (P < .001). One of the explanations for this difference
could be related to the longer exposure times in the outpatient
household compared with the hospital setting.
Detection Dynamics of ESBL Producers Not Linked
to Transmission
A considerable number of ESBL producers detected by screen-
ing of hospital contact patients or household contacts could
not be explained by transmission to an index patient (Supple-
mentary Figure 1). In the hospital setting, this proportion was
slightly higher than the prevalence of nosocomial transmis-
sions for both ESBL-Ec (5.7% vs 4.5%) and ESBL-Kp (16.7% vs
8.3%). In particular, the dynamics of detection of ESBL pro-
ducers in contact patients was quite similar for transmission
and nontransmission events (Figure 4A). Probably, detection
of ESBL producers requires some selection process (eg, expo-
sure to antibiotics), which ﬂuctuates during hospitalization.
Thus, standard screenings (eg, selective agar plates) performed
Figure 2. Characteristics of hospital transmissions from index patients to hospital contacts of extended-spectrum β-lactamase (ESBL)-producing Kleb-
siella pneumoniae and Escherichia coli. Sequence types (ST) are shown according to Pasteur (K. pneumoniae) and Achtman (E. coli ) multilocus se-
quence typing (MLST) scheme. Furthermore, E. coli isolates of group B2 that are positive for the pabB gene are indicative for ST131 according to
Achtman MLST scheme. Initial screening of feces samples revealed identical results for 8 patients. For the remaining, 2 ESBL-producing E. coli instead
of initial ESBL-producing K. pneumoniae were detected (ie, index patients 186 and 115), whereas 1 negative stool sample results was obtained (ie,
patient 110). Abbreviations: Ec, Escherichia coli; HC, hospital contact; ICU, intensive care unit; Kp, Klebsiella pneumoniae; PFGE, pulse-ﬁeld gel electro-
phoresis; rep-PCR, extragenic palindromic polymerase chain reaction; ST, sequence type.
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at one time point only (eg, at hospital entry) might therefore
not identify all ESBL carriers. In the household setting, chance
ﬁndings of ESBL carriage were less frequent than transmission
events (ESBL-Ec, 12.5% vs 22.7%; ESBL-Kp, 0% vs 25%).
However, the dynamics of ESBL detection over time were
again quite similar for both groups (Figure 4B).
Limitations of This Study
Our study has several limitations. First, the criteria for trans-
mission in this study did not address the possibility of hori-
zontal transmission of common plasmids among different
Enterobacteriaceae species [35]. Thus, transmission rates
might have been underestimated, but this hypothetical bias
should have affected both household and hospital transmis-
sions to the same extent. Second, our study could not
address whether household transmission occurred from the
index patients to other household members or by acquisition
from a common source. In fact, several studies have sug-
gested that common sources such as food may contribute
to the dissemination ESBL producers [12, 36]. However, for
2 household contacts (household contacts 118 and 158)
person-to-person transmission was likely, because in both
cases the corresponding patients (patients 110 and 70) ac-
quired the ESBL producer during their hospital stay and
transmitted it probably subsequently to their household con-
tacts (Figure 3). In addition, the high prevalence of CTX-M-
15-producing EBSL-Ec of ST131 also indicates person-to-
person transmission because humans are the main reservoir
of this clone [6, 37]. Overall, based on our data, we speculate
that patients recently discharged from a hospital or cared for
as outpatients may be a more efﬁcient source of transmission
in the community than healthy carriers. Whether such trans-
mission can be controlled by preventative measures has to be
evaluated.
Figure 3. Characteristics of household transmissions of extended-spectrum β-lactamase–producing Escherichia coli and Klebsiella pneumoniae. Index
patients, hospital contacts, and household contacts are indicated. Household clusters are shown in boxes. Presence of pabB gene is illustrated.
Sequence types were determined according to Pasteur (K. pneumoniae ) and Achtman (E. coli ) multilocus sequence typing scheme. Abbreviations: Ec,
Escherichia coli; HC, hospital contact; HHC, household contact; Kp, Klebsiella pneumoniae; PFGE, pulse-ﬁeld gel electrophoresis; rep-PCR, extragenic
palindromic polymerase chain reaction; ST, sequence type.
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Conclusions
To our knowledge, this is the ﬁrst epidemiological study ana-
lyzing the transmission rates of ESBL producers in the house-
hold and the hospital setting simultaneously (ie, within the
same period, within the same geographic area, and with the
same index patients). Our data indicate that household trans-
mission outweighs hospital transmission in a non-outbreak
scenario and household transmission is enhanced in the pres-
ence of index patients recently discharged or cared for in a
hospital. Furthermore, in the non-outbreak setting, importa-
tion of ESBL producers into the hospitals seems to be at least
as frequent as transmission events during hospital stay. Our
data also suggest that ESBL-Kp may be more efﬁciently trans-
mitted within the hospital than ESBL-Ec and question the
effect of infection control measures among different species.
Further studies are needed to address the last issue.
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